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The interleukin-8 promoter is transcriptionally activated by interleukin-1, tumor necrosis factor alpha,
phorbol myristate acetate, or hepatitis B virus X protein through a sequence located between positions -91 and
-71. This region contains an NF-KB-like and a C/EBP-like binding site. We show here that several members
of the NF-cB family, including p65, p50, p52, and c-Rel, can bind to this region, confirming an authentic
NF-cB binding site in the interleukin-8 promoter. Further, C/EBP binds only weakly to the interleukin-8
promoter site. Electrophoretic mobility shift assays with proteins overexpressed in COS cells and with nuclear
extracts from tumor necrosis factor alpha-stimulated HeLa cells demonstrated a strong cooperative binding of
C/EBP to its site when NF-cB is bound to its adjacent binding site. Transfection studies lead to a model that
suggests a highly complex regulation of interleukin-8 gene expression at multiple levels: independent binding
of C/EBP and NF-KB to their respective sites, cooperative binding of C/EBP and NF-KB to DNA, and positive
synergistic activation through the C/EBP binding site and inhibition through the NF-KB binding site by
combinations of C/EBP and NF-KB. Thus, the ultimate regulation of interleukin-8 gene expression depends on
the ratio of cellular C/EBP and NF-cB.
Regulation of gene expression at the transcriptional level
is mediated by transcription factors binding to cis-acting
DNA elements in the promoter regions of the respective
genes. Transcription factors can act as activators or inhibi-
tors of gene transcription. In addition, many genes are
controlled by simultaneous binding of diverse transcription
factors to cis-acting DNA elements in the same promoter.
Recently a novel mechanism of gene regulation has emerged;
in this mechanism, cross-family interaction, one transcrip-
tion factor modulates the activity of another by direct
physical interaction. Examples are the interaction between
the glucocorticoid receptor and the AP-1 proteins Jun and
Fos (15, 21, 27, 38, 44) and the interaction of Jun with MyoD
(8). We have recently shown the functional and physical
association of NF-KB family members with Jun/Fos proteins
(39) and with C/EBP family members (40). The interaction
with C/EBP results in the inhibition of promoters with KB
enhancer motifs and in synergistic stimulation of promoters
with C/EBP binding sites. NF-KB and C/EBP are activated
by important inflammatory cytokines such as interleukin-1
(IL-1) and IL-6, respectively (34, 35). Therefore, the inter-
action between NF-KB and C/EBP might be involved in
T-cell activation and the acute-phase response (1, 19, 42). In
this regard, several promoters that have closely spaced
NF-KB and C/EBP binding sites have been cloned. Exam-
ples are the acute-phase response gene encoding serum
amyloid Al as well as the angiotensinogen, IL-6, and IL-8
genes (12, 20, 26, 29).
IL-8 is a novel cytokine that is produced by a variety of
human somatic cells and several types of human tumor cell
lines (references 24 and 45 and references therein). IL-8 has
T-cell, neutrophil, and basophil chemotactic properties (for a
review, see reference 28). The production of IL-8 is not
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constitutive and can be induced by various agents such as
lipopolysaccharides, IL-1, tumor necrosis factor alpha
(TNF-a), and phorbol myristate acetate (PMA) (for a re-
view, see 28). Deletion analyses of the IL-8 promoter
showed that the sequences between positions -91 and -71
are necessary and sufficient for the induction of IL-8 gene
transcription by IL-1, TNF-a, and PMA in human fibrosar-
coma cells (29). This region of the promoter contains a
putative C/EBP and a putative NF-KB binding site.
In this study, we show that several members of the NF-KB
family can bind to the proposed KB enhancer motif found in
the IL-8 promoter. We further show that binding of NF-KB
to its site results in the strong cooperative binding of C/EBP
to its adjacent site. Treatment of HeLa cells with TNF-a
induces a similar cooperative binding of these factors to
DNA. We propose a highly complex regulation of IL-8 gene
expression by distinct mechanisms involving binding of
C/EBP and NF-KB family members to cis DNA elements as
well as physical protein-protein interactions of C/EBP with
NF-KB.
MATERIALS AND METHODS
Plasmid constructs. The C/EBP-TATA-chloramphenicol
acetyltransferase (CAT) reporter plasmid has been described
elsewhere (40). The IL-8 wt (wild-type) reporter was gener-
ated by cloning a single copy of an oligonucleotide en-
compassing the bp -97 to -69 region of the human IL-8
gene (5'-AGCTTCATCAGTTGCAAATCGTGGAATmTCC
TCTG-3') (binding sites for C/EBP and NF-KB are in bold-
face type) into HindIII-BamHI-cut TATA-CAT. The IL-8
mKB-TATA-CAT and IL-8 mC/EBP-TATA-CAT reporter
plasmids contain oligonucleotides with point mutations in
the NF-KB binding site (5'-AGCTTCATCAGTTGCAAAT
CGTITAACTfTTCCTCTG-3') (point mutations are under-
lined) and the C/EBP binding site (5'-AGCTTCATCAGC
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TACGAGTCGTGGAATTTCCTCTG-3') (point mutations
are underlined), respectively. Plasmids pCMV4T, pCMV4T-
p65, pCMV4T-p50, and pCMV4T-rC/EBPj have been de-
scribed previously (40). The expression vector pCMV4T-hc-
Rel is described elsewhere (5).
Transfection of cells and analysis of CAT activity. All cell
lines were cultured in Iscove's Dulbecco modified Eagle
medium supplemented with 7.5% fetal calf serum and anti-
biotics. Mouse F9 embryonal carcinoma cells were tran-
siently transfected by the calcium phosphate method (17).
HeLa cells were transiently transfected with plasmid DNA
by the DEAE-dextran method (22). CAT enzymatic activity
was assayed as previously described (32) and normalized for
protein recovery (11).
Extract preparation. Whole-cell extracts from COS cells
transfected with NF-KB expression vectors were prepared
by a method used to prepare CAT assay extracts (2) 3 days
posttransfection. Nuclear extracts from HeLa cells were
prepared as described elsewhere (41) and were a generous
gift of Amer A. Beg. Mouse C/EBPO protein expressed in
bacteria (14) was -a generous gift of Steven L. McKnight.
EMSAs. Electrophoretic mobility shift assays (EMSAs)
were performed as previously described (41). The binding
buffer contained 12 mM N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid (HEPES)-NaOH (pH 7.9), 4 mM Tris-
(pH 7.9), 60 mM KCl, 5 mM MgCl2, 0.6 mM EDTA, 12%
glycerol, and 5 mM dithiothreitol. The IL-8 wt binding site
was created by annealing the two oligonucleotides 5'-AGCT
TCATCAGTTGCAAATCGTGGAATTTCCTCTG-3' and 5'-
TAGCCAGAGGAAATTCCACGATTTGCAACTGATGA-3'
(binding sites for C/EBP and NF-KB are in boldface type).
The IL-8 mKB binding site was created by annealing the two
oligonucleotides 5'-AGCTTCATCAGTTGCAAATCGTTA
ACTTTCCTCTG-3' and 5'-TAGCCAGAGGAAA-Gj1IAAC
GATTTGCAACTGATGA-3' (point mutations are under-
lined). The IL-8 mC/EBP binding site was created by anneal-
ing the two oligonucleotides 5'-AGCTfCATCAGCTA
C-AGTCGTGGAATTTCCTCTG-3' and 5'-TAGCCAGA
GGAAATTCCACGACTCGTMACTGATGA-3' (point muta-
tions are underlined). The 65-2 and human immunodefi-
ciency virus type 1 (HIV-1) KB oligonucleotides have been
described elsewhere (25), as have the oligonucleotide with a
core C/EBP binding site derived from the c-fos serum
response element (40) and the AP-1 oligonucleotide encom-
passing the collagenase promoter AP-1 binding site (3).
Antibodies. Anti-p65 is antiserum raised against an N-ter-
minal peptide of NF-KB p65 (7). Anti-p5O antiserum was
obtained from Alain Israel, anti-c-Rel antiserum was ob-
tained from Nancy Rice, anti-C/EBP, antiserum was ob-
tained from Steven McKnight, and anti-p52 antiserum was
obtained from Michael Karin. Antisera (1 ,u) were added to
EMSA reaction mixtures for 1 h at 4°C prior to addition of
the radiolabeled probe.
RESULTS
Cooperative binding of NF-cB and C/EBP to the IL-8
promoter. The IL-8 promoter has been previously cloned
and sequenced (30). The 5' flanking promoter region con-
tains potential binding sites for AP-1, AP-2, interferon reg-
ulatory factor 1, hepatocyte nuclear factor 1, glucocorticoid
receptor, C/EBP, and NF-KB (29). Promoter deletion analy-
ses showed that sequences between positions -91 and -71
are necessary and sufficient for the responsiveness to IL-1,
TNF-a, and PMA in human fibrosarcoma cells (29). This
region contains potential binding sites for C/EBP and NF-
KB.
To study whether NF-KB family members can bind to the
IL-8 promoter, EMSAs were performed with an oligonucle-
otide probe (IL-8 wt) encompassing the region between -97
bp and -69 bp and therefore containing both the potential
C/EBP and NF-KB binding sites. Several COS cell-ex-
pressed NF-KB family members, including NF-KB p65,
NF-KB p50, NF-KB pSO/p65 heterodimers, and c-Rel, bound
specifically to the IL-8 wt probe (Fig. 1A, lanes 7 to 10),
while no binding activity was detected with control extracts
from mock-transfected COS cells (lane 6). Bacterially ex-
pressed C/EBP, showed only weak binding by itself to IL-8
wt (lane 1) but caused a supershifted band in the presence of
several different NF-KB proteins (lanes 2 to 5). We found the
strongest supershift with NF-KB p65 (lane 2), while a super-
shift with NF-KB p50 was detectable only after longer
exposure of the gel (lane 3 and data not shown). The
supershifted band indicates that the binding of C/EBP is
strongly stimulated when NF-KB is bound to its adjacent site
and that the two factors bind to the same oligonucleotide. An
approximate fold increase in binding of C/EBP in the pres-
ence of NF-KB can be calculated by comparing the relative
intensity of the supershifted complex with that of the com-
plex of C/EBP alone. The increase in NF-KB p65 binding is
represented by the same calculated ratio and is much lower
since NF-KB already binds to the IL-8 site with high affinity.
We were next interested in whether C/EBP and NF-KB are
able to occupy their respective adjacent cis-acting DNA
elements at the same time. For this study, we used three
different oligonucleotide probes, IL-8 wt, IL-8 mKB with
point mutations in the KB enhancer motif, and IL-8 mC/EBP
with point mutations in the C/EBP binding site. EMSAs with
bacterially expressed C/EBPP showed that C/EBPI bound
to IL-8 wt and IL-8 mKB, although weakly with the amounts
used (Fig. 1B, lanes 1 and 4). NF-KB p65 expressed in vivo
in COS cells bound to IL-8 wt and IL-8 mC/EBP (lanes 3 and
9). This finding indicates that the point mutations in IL-8
mKB and IL-8 mC/EBP disrupt only the targeted binding site
and that C/EBP,B as well as NF-KB can bind by themselves
to their respective sites. When we added a combination of
C/EBPP and NF-KB, a strong supershifted band was ob-
served with the wild-type probe only (lane 2). This result and
the absence of supershifted bands with IL-8 mKB and IL-8
mC/EBP clearly demonstrate a cooperative binding of
C/EBP to its target sequence when NF-KB is bound to its
high-affinity site.
Analysis of NF-cB family member binding to the IL-8
promoter. To ultimately define the functional properties of
the NF-KB binding site in the IL-8 promoter, we compared
this site with sequences listed in a recent publication (25).
The IL-8 promoter NF-KB binding site matches, over the
core KB consensus element, a DNA sequence termed 65-9.
This sequence is listed as a selective NF-KB binding site that
excludes binding of NF-KB p50 and NF-KB pSO/p65 het-
erodimers (25). Our results (Fig. 1A) with proteins expressed
in COS cells clearly demonstrated binding of NF-KB pSO/p65
heterodimers and NF-KB p50 to this site. To further analyze
this, we compared binding of NF-KB p65 homodimers,
NF-KB p50 homodimers, and NF-KB pSO/p65 heterodimers
to the HIV-1 KB enhancer, a site known to bind all three
forms, with that of 65-2, another selective NF-KB binding
site described as not binding to NF-KB p50 homodimers or to
NF-KB pSO/p65 heterodimers (25), and with that of the IL-8
wt site. All three COS cell-expressed NF-KB forms were
able to bind to the three different probes (Fig. 2A). It
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FIG. 1. Cooperative binding of NF-KB and C/EBP to the IL-8 promoter. (A) Extracts from COS cells transiently transfected with a control
vector (CMV4T) or expression vectors for NF-K<B family members were incubated in the presence (lanes 1 to 5) or absence (lanes 6 to 10)
of bacterially expressed C/EBPP for 15 min at room temperature (RT) in EMSA buffer with 0.1 SLg of poly(dI-dC) and 5 Fg of bovine serum
albumin (BSA). After addition of 32P-labeled probe (IL-8 wt) and incubation at RT for 30 min, DNA-protein complexes were analyzed by
EMSA with 0.25 x Tris-borate-EDTA native gels. (B) Bacterially expressed C/EBPI and COS cell-expressed NF-KB p65 were incubated as
indicated for 15 min at RT in EMSA buffer with 0.1 of Fg poly(dI-dC) and 5 ,ug of BSA. After addition of 32P-labeled probe (IL-8 wt, lanes
1 to 3; IL-8 mKB, lanes 4 to 6; IL-8 mC/EBP, lanes 7 to 9) and incubation at RT for 30 min, DNA-protein complexes were analyzed by EMSA
with 0.25 x Tris-borate-EDTA native gels. The arrows indicate the positions of the respective protein-DNA complexes. All COS
cell-expressed NF-KB family members were produced at similar levels, as assessed by Western blot analysis (data not shown).
appeared that 65-2 and IL-8 wt preferred the heterodimer
over the respective homodimers (Fig. 2A, lanes 5 and 8). We
also analyzed binding of nuclear extracts from TNF-a-
treated HeLa cells to these three probes (Fig. 2B). We used
IL-8 mC/EBP as the binding site instead of IL-8 wt to
exclude any interference on NF-KB binding coming from the
C/EBP binding site (see below). EMSAs demonstrated the
presence of two specific DNA-protein complexes, termed II
and III, with all three probes. Complex II was characterized
to contain heterodimers of NF-KB p65 with other members
of the NF-KB family and possible NF-KB p65 homodimers,
while complex III contains NF-KB p5O/p65 heterodimers and
a potential p50/Rel heterodimer (6) (Fig. 3C and data not
shown). These data confirm our results with the COS pro-
teins indicating that all three probes are capable of binding
NF-KB p50/p65 heterodimers, although the IL-8 probe pref-
erentially forms complex II with HeLa nuclear extracts. To
further analyze this issue, we tested binding of bacterially
expressed NF-KB p50 (a gift from C. Rosen) to these sites.
Consistent with the data of Kunsch et al. (25), bacterially
expressed NF-KB p50 did not bind to 65-2 and IL-8 wt (data
not shown). This finding strongly suggests that a modifica-
tion of NF-KB and/or the source and kind of purification of
NF-KB have a strong influence on its binding characteristics.
In conclusion, the three binding sites analyzed here, includ-
ing the IL-8 element, do not exclude binding of NF-KB p50
and NF-KB pSO/p65.
Cooperative binding of NF-KB and C/EBP after TNF-a
stimulation. Our in vitro binding studies clearly demon-
strated cooperative binding of C/EBP and NF-KB to an IL-8
promoter element that has been reported to mediate induc-
tion by TNF-a (29). To analyze which proteins in cells bind
to this IL-8 promoter sequence, we performed EMSAs with
nuclear extracts from unstimulated and TNF-a-treated
HeLa cells (Fig. 3A). We selected HeLa cells for these
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FIG. 2. Analysis of binding of NF-KB family members. (A) Ex-
tracts from COS cells transiently transfected with pCMV4T-p65,
pCMV4T-p50, or a combination of the two were incubated at RT in
EMSA buffer with 0.1 pg of poly(dI-dC) and 5 jig of BSA. After
addition of 32P-labeled probe (HIV-1 KB, lanes 1 to 3; 65-2, lanes 4 to
6; IL-8 wt, lanes 7 to 9) and incubation at RT for 30 min, DNA-protein
complexes were analyzed by EMSA with 0.25x Tris-borate-EDTA
native gels. The arrows indicate the positions of the respective
NF-KB-DNA complexes. (B) Nuclear extracts from HeLa cells
prepared 1 h after treatment with TNF-a (10 ng/ml; Genentech) were
incubated at RT in EMSA buffer with 0.5 pg of poly(dI-dC). After
addition of 32P-labeled probe (HIV-1 KB, lane 1; 65-2, lane 2; IL-8
mC/EBP, lane 3) and incubation at RT for 30 min, DNA-protein
complexes were analyzed by EMSA with 0.25x Tris-borate-EDTA
native gels. The arrows indicate the positions of two specific DNA-
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FIG. 3. Cooperative binding of NF-KB and C/EBP after TNF-a stimulation. (A) Nuclear extracts from HeLa cells treated for 1 h with
TNF-a (10 ng/ml; Genentech) (lane 3) or left untreated (con, lane 2) were incubated at RT in EMSA buffer with 0.5 Fg of poly(dI-dC). For
comparison, lane 1 shows binding of NF-KB p50 and NF-KB p65 expressed in COS cells. After addition of 32P-labeled probe (IL-8 wt) and
incubation at RT for 30 min, DNA-protein complexes were analyzed by EMSA with 0.25x Tris-borate-EDTA native gels. (B) Nuclear
extracts from HeLa cells prepared for 1 h after treatment with TNF-a (10 ng/ml; Genentech) were incubated at RT in EMSA buffer with 0.5
jg of poly(dI-dC) and a 100-fold molar excess of each of the indicated competitor oligonucleotides. After addition of 32P-labeled probe (IL-8
wt, lanes 1 to 6; IL-8 mKB, lane 7; IL-8 mC/EBP, lane 8) and incubation at RT for 30 min, DNA-protein complexes were analyzed by EMSA
with 0.25x Tris-borate-EDTA native gels. (C) Nuclear extracts from HeLa cells prepared 1 h after treatment with TNF-a (10 ng/ml;
Genentech) were incubated for 1 h at 4°C in EMSA buffer with 0.5 ,g of poly(dI-dC) and 1 ,ul of each of the indicated antibodies or normal
rabbit serum (NRS, lane 1). After addition of 32P-labeled probe (IL-8 wt) and incubation at RT for 30 min, DNA-protein complexes were
analyzed by EMSA with 0.25 x Tris-borate-EDTA native gels. The arrows indicate the positions of three specific DNA-protein complexes (I,
II, and III) and a nonspecific complex (NS).
binding studies because the NF-KB protein complexes in
HeLa cells are relatively well characterizedt Stimulation of
cells for 1 h with TNF-ct leads to a strong increase in
formation of three DNA-protein complexes, termed I, II,
and III, to the IL-8 wt probe (Fig. 3A; compare lanes 2 and
3). The band labeled NS as well as the faster-migrating band
are nonspecific (see below) and are not affected by TNF-ct
treatment. Complex II migrates similarly to NF-KB p65
homodimers, and complex III migrates like NF-KB p50/p65
heterodimers (compare lane 3 with lane 1). Competition
analyses with C/EBP binding sites (IL-8 mKB and C/EBP)
demonstrated that complex I depends on C/EBP binding
(Fig. 3B, lanes 2 and 5). Competition analyses with NF-KB
binding sites (IL-8 mC/EBP and HIV-1 KB) showed the
presence of NF-KB factors in complexes I, II, and III (lanes
3 and 4). An unrelated oligonucleotide (AP-1) did not com-
pete for binding. We further confirmed these data by using
IL-8 mKB and IL-8 mC/EBP as radiolabeled probes (lanes 7
and 8). From these experiments, we conclude that complex
I contains both NF-KB and C/EBP factors and that com-
plexes II and III contain NF-KB protein. The band labeled
NS is not affected by the competitors.
Antibody studies confirmed our EMSA competition data.
Antibodies against NF-KB p65 strongly diminished com-
plexes I, II, and III (Fig. 3C, lane 2). Anti-p5O slightly
diminished complex I, did not affect complex II, and blocked
formation of complex III. Anti-p52 blocked formation of
complex II only. The slight difference in complex I migration
in the presence of anti-p52 antibodies is likely caused by
different concentrations of proteins and buffer due to the
antiserum. Anti-c-Rel diminished all three EMSA protein
complexes weakly. Anti-C/EBPI abolished complex I only
and resulted in a supershifted band (Fig. 3C, lane 6). From
these data, we conclude that NF-KB p65 and to a lesser
extent c-Rel participate in complexes I, II, and III, while
NF-KB p50 participates in complex III and in smaller
amounts in complex I. Complex II contains predominantly
NF-KB p65 and NF-KB p52, and complex III seems to be an
NF-KB p5O/p65 and p5O/Rel heterodimer. In conclusion,
most of the supershifted complex I contains NF-KB p65 and
C/EBP. This finding is consistent with the data shown in Fig.
1A, which demonstrate strongest cooperative binding of
C/EBP with NF-eB p65 but only weak cooperativity with
NF-icB p5O.
Complex regulatory mechanisms play a role in IL-8 gene
activation. We have previously shown that NF-KB and
C/EBP functionally and physically interact. This cross-
coupling results in inhibition of promoters with NF-KB
binding sites and in synergistic stimulation of promoters with
C/EBP binding sites (40). The IL-8 promoter is an example
of a promoter in which the two binding sites are located close
together. Our in vitro experiments showed a cooperative
binding of NF-KB and C/EBP to their adjacent binding sites.
Therefore, we were interested how NF-KB and C/EBP
regulate the IL-8 promoter in vivo. We selected F9 embryo
carcinoma cells for these studies because of their very low
levels of endogenous nuclear NF-KB activity. Since the IL-1,
TNF-a, and PMA responsiveness of the IL-8 promoter in
fibrosarcoma cells was narrowed down to sequences be-
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FIG. 4. Cross-coupling of NF-KB and C/EBP. Mouse F9 embryonal carcinoma cells were transiently transfected with 8 ,ug of CAT reporter
plasmid IL-8 wt-TATA-CAT, IL-8 mKB-TATA-CAT, or IL-8 mC/EBP-TATA-CAT and increasing amounts (0.1 to 6 ,ug) of pCMV4T-p65 (A)
or pCMV4T-rC/EBPP (B) expression vector. (C) Mouse F9 embryonal carcinoma cells were transiently transfected with 8 1Lg of CAT reporter
plasmid IL-8 wt-TATA-CAT, 6 pLg of pCMV4T-rC/EBPO, and increasing amounts of pCMV4T-p65. (D) Mouse F9 embryonal carcinoma cells
were transiently transfected with 8 ,ug of CAT reporter plasmid IL-8 wt-TATA-CAT, 0.1 ,ug of pCMV4T-p65, and increasing amounts of
pCMV4T-rC/EBP,. (E) Mouse F9 embryonal carcinoma cells were transiently transfected with 8 ,ug of CAT reporter plasmid IL-8
mKB-TATA-CAT or IL-8 mC/EBP-TATA-CAT and 0.1 ,ug of pCMV4T-p65, 6 p,g of pCMV4T-rC/EBPI3, or a combination of the two. The
total amount of transfected DNA was held constant by the addition of the parental pCMV4T vector. Six hours after transfection, CAT activity
was determined. CAT activity is presented as fold induction relative to activity obtained with transfected pCMV4T alone. Values shown
represent the normalized mean inductive responses from at least three independent experiments. The standard errors were consistently less
than 20% of the means.
moter constructs for these studies. These constructs contain
the same oligonucleotides used for the EMSAs encompass-
ing only the C/EBP and NF-KB binding sites positioned in
front of a TATA box linked to the CAT reporter gene.
NF-KB p65 is a very efficient activator of IL-8 wt TATA-
CAT and IL-8 mC/EBP-TATA-CAT reporter genes, while
the point mutations in the NF-KB binding site (IL-8 mKB-
TATA-CAT) abolished inducibility by NF-KB p65 (Fig. 4A).
Consistent with our EMSAs, C/EBP activates the IL-8
promoter very weakly at higher concentrations only (Fig.
4B). Transfection of IL-8 wt-TATA-CAT with a constant
amount of C/EBP and increasing amounts of NF-KB p65
resulted in a dose-dependent increase of CAT activity (Fig.
4C). When we cotransfected the IL-8 wt-TATA-CAT re-
porter with NF-KB p65 and increasing amounts of C/EBP,
we observed an increase or an inhibition of CAT activity,
depending on the ratio of NF-KB p65 and C/EBP (Fig. 4D).
As stated above, NF-KB and C/EBP synergistically activate
promoters with C/EBP binding sites but inhibit promoters
with KB binding sites. Since the IL-8 promoter has binding
sites for both factors, we suspected a highly complex regu-
lation depending on the ratio of both factors. To test this
hypothesis, we cotransfected NF-KB p65 and C/EBP to-
gether with IL-8 mC/EBP-TATA-CAT, a KB-dependent pro-
moter. As expected, C/EBP inhibited the induction by
NF-KB p65 (Fig. 4E). The inhibition by C/EBP was dose
dependent and never resulted in an increase of CAT activity
(data not shown). Cotransfection of NF-KB p65 and C/EBP
with a C/EBP-dependent promoter, IL-8 mKB-TATA-CAT,
resulted in strong synergistic activation (Fig. 4E). Under
comparable conditions, the induction of the IL-8 wt pro-
moter by NF-KB p65 was inhibited by C/EBP (compare with
Fig. 4D, 3 ,ug of C/EBPI expression vector). Thus, the IL-8
promoter combines the properties of a KB- and a C/EBP-
dependent promoter. Western blot (immunoblot) analyses
showed that NF-KB p65 had no effect on the expression of
cotransfected C/EBP expression vectors and, vice versa,
that C/EBP did not change the expression of cotransfected
NF-KB p65 expression vectors (40). These results suggest
that distinct nuclear factors, NF-KB and C/EBP, bind to
independent cis DNA elements in the IL-8 promoter, al-
though their binding under nonstimulated conditions is likely
to be weak. However, treatment of cells with cytokines such
as TNF-a results in cooperative binding of C/EBP and
NF-KB to their adjacent binding sites. IL-8 gene expression
is further regulated by protein-protein interactions between
C/EBP and NF-KB. This results in synergistic activation
through the C/EBP binding site and in antagonistic inhibition
through the NF-KB binding site (see Discussion and Fig. 5
for a model of IL-8 gene regulation).
DISCUSSION
The IL-8 promoter is transcriptionally activated by vari-
ous agents such as IL-1, TNF-a, and the hepatitis B virus X
protein. Further, by using several deletion mutants, it has
been shown that a cis DNA element between positions -91
and -71 is necessary for the induction of the IL-8 gene by
these agents in fibrosarcoma cells. This DNA region was
described as a putative C/EBP-like and a putative NF-KB-
like binding site. It has been reported that both sites coop-
erate in the induction of the IL-8 gene, but it has not been
shown that this is actually caused by a cooperative binding
of C/EBP and NF-KB to this region (29). Since NF-KB DNA
binding activity is increased by IL-1 and TNF-a, we wanted
to analyze whether NF-KB is able to target the IL-8 promoter
KB-like binding site and whether NF-KB cooperatively binds
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Our experiments clearly demonstrate the cooperative
binding of NF-KB and C/EBP to their adjacent binding sites.
NF-KB and C/EBP are two important transcription factor
families that are involved in immune and inflammatory
functions as well as cell growth and differentiation. NF-KB is
typically composed of a 50-kDa (10, 16, 23) and a 65-kDa (33,
36) subunit that share with other members of this family,
such as c-Rel (13, 18) and NF-KB p52 (9, 31, 37), the highly
homologous N terminus, the so-called Rel homology do-
main. NF-KB family members bind as a dimer to a relatively
well-conserved sequence that is found in a variety of genes
(4). While NF-KB p65, p50, and c-Rel bound efficiently to the
IL-8 KB site, C/EBPP, a member of the bZIP family of
transcription factors (43), bound only weakly to the C/EBP
binding site in the IL-8 promoter (Fig. 1). The formation of a
slower-migrating DNA-protein complex (supershift) indi-
cates that the two factors bind to the same oligonucleotide.
Competition analyses and selective mutation of either bind-
ing site demonstrated that NF-KB and C/EBP bind simulta-
neously to their adjacent binding sites (Fig. 1). The strongest
supershift was observed with NF-KB p65, and the weakest
was observed with NF-KB p50. This is also reflected by our
EMSA studies with extracts from TNF-a-stimulated HeLa
cells (Fig. 3). While anti-p5O antibodies had only a weak
effect on the supershifted band (complex I), anti-p65 anti-
bodies totally abolished this complex, although this does not
rule out the presence of NF-KB p5O/p65 heterodimers in
complex I (see below). Interestingly, it appears that NF-KB
p52 does not participate in the supershifted complex. The
remaining complex II consists predominantly of NF-KB
p65/p52 heterodimers. The fact that complex II with a major
histocompatibility complex KB site has been shown to con-
tain, in addition to p65/p5Z heterodimers, NF-KB p65/Rel
heterodimers and possibly NF-KB p65 homodimers (6) sug-
gests that an NF-KB dimer containing p52 may not interact
with C/EBP. C-Rel is present in all three complexes at the
IL-8 promoter in small amounts. Anti-C/EBP,B antibodies
completely shifted the supershifted band but did not affect
the other complexes, indicating the presence of C/EBP
family members in complex I. We cannot completely rule
out that other members of the NF-KB family are also present
together with C/EBP in this supershifted complex but are not
efficiently recognized by the respective antisera.
We were unable to detect any binding of C/EBP alone to
the IL-8 wt oligonucleotide with extracts from TNF-a-
stimulated HeLa cells, and experiments with bacterially
expressed C/EBPP showed binding of C/EBP that was much
weaker than NF-KB binding. This finding suggests that all
DNA-bound C/EBP is in the supershifted complex I predom-
inantly together with NF-KB p65. The cooperative binding of
C/EBP and NF-KB is most likely based on a direct protein-
protein interaction. C/EBP physically interacts through its
bZIP region with the Rel homology domain of NF-KB family
members such as NF-KB p65 and p50 (40). This interaction
results in synergistic activation of promoters with C/EBP
binding sites and in inhibition of promoters with NF-KB
binding sites (40). We cannot exclude that the binding of
NF-KB to DNA also results in a conformational change
(DNA bending) of the C/EBP binding site increasing the
affinity for C/EBP.
Our in vitro binding studies are complemented by in vivo
functional studies. We selected F9 mouse embryo carcinoma
cells for these studies since these cells do not express
endogenous NF-KB. As expected from our in vitro data,
increasing amounts of NF-KB p65 expression vector lead to
strong activation of IL-8 wt-TATA-CAT and IL-8 mC/EBP-
CAGTTGCAAATCGT|GGAA1 CCT
FIG. 5. Model for binding of C/EBP and NF-KB to their adjacent
binding sites in the IL-8 promoter. 33, cooperativity of C/EBP and
NF-KB; I®. positive synergistic activation of C/EBP by NF-KB;
E), inhibition of NF-KB by C/EBP.
TATA-CAT reporters. On the other hand, we were unable to
detect any specific activation of IL-8 promoter constructs by
the C/EBP expression vector. This finding confirms our
EMSA data demonstrating that C/EBP in the absence of
NF-KB binds only very weakly.
Interestingly, cotransfection of NF-KB p65 and C/EBP
demonstrated that the IL-8 promoter behaves like a C/EBP-
dependent and an NF-KB-dependent promoter. The ratio of
NF-KB p65 and C/EBP determines whether the IL-8 pro-
moter is activated or inhibited (Fig. 4D and E). Further,
when the C/EBP binding site was mutated (IL-8 mC/EBP),
C/EBP inhibited the induction by NF-KB p65 (Fig. 4E). This
is similar to results that we obtained with other NF-KB-
dependent promoters (40). In contrast, when the NF-KB
binding site was mutated, the cotransfection of NF-KB and
C/EBP resulted in strong synergistic activation of IL-8
mKB-TATA-CAT (Fig. 4E). This is similar to results that we
obtained with C/EBP-dependent promoters (40). These data
suggest that the mechanism of synergistic activation of IL-8
mKB-TATA-CAT is mainly dependent on increased tran-
scriptional activity rather than increased DNA binding (Fig.
1B, lane 5) (40).
It has been shown previously that both the C/EBP and
NF-KB binding sites are necessary for TNF-a induction of
the IL-8 promoter (29). These transfection studies were done
in cells with a constitutive amount of endogenous C/EBP
(29). TNF-oa increases the amount of active NF-KB in the
nucleus, which, according to our model, will cooperatively
stimulate binding of C/EBP to the IL-8 promoter. A mutation
in the C/EBP binding site will still allow binding of NF-KB to
its site, but the physical interaction of C/EBP with NF-KB
may result in an inhibition of KB-dependent gene transcrip-
tion (40). In contrast, our transfection studies in F9 cells
were done with an excess of NF-KB p65 and very low
amounts of endogenous C/EBP. Under these conditions,
NF-KB p65 by itself will be able to activate the IL-8 gene
through the KB binding site.
We therefore propose that the IL-8 promoter has a highly
complex regulation by three potential mechanisms (Fig. 5).
The first level of regulation is the binding of C/EBP or
NF-KB to their respective binding sites. This results at least
for NF-KB in positive transcriptional regulation (Fig. 4A). It
should be stated that in unstimulated cells, neither C/EBP
nor NF-KB may be able to bind to the IL-8 promoter. The
second level of regulation is the cooperative binding of
C/EBP and NF-KB to their adjacent binding sites. From our
in vitro binding studies, we believe that a C/EBP-NF-KB-
DNA complex is highly preferred over a C/EBP-DNA or
NF-KB-DNA complex (Fig. 1 and 3). The third level of gene
regulation is a new mechanism delineated from our previous
publication (40). If NF-cB is in excess, it may interact with
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C/EBP bound to the C/EBP site, which then results in
positive synergistic activation through the C/EBP binding
site (Fig. 4E). On the other hand, an excess of C/EBP will
inhibit NF-KB bound to the KB binding site (Fig. 4E). This is
also shown by cotransfecting IL-8 wt-TATA-CAT with a
constant amount of NF-KB p65 and two different amounts of
C/EBP (Fig. 4D). If cooperative binding of C/EBP and
NF-KB to the IL-8 site occurs, this will likely exclude both of
the other two mechanisms.
The conditions in the cell that favor the active versus the
inactive state of transcription are likely to be complex. IL-1,
TNF-a, PMA, and hepatitis B virus X protein are all
activators of IL-8 gene transcription. These agents are also
known to activate NF-KB. Further, multimerized IL-8
NF-KB binding sites, in contrast to multimerized C/EBP
binding sites, are sufficient to mediate activation by these
agents (29). This finding suggests that NF-KB plays the more
important role in IL-8 gene regulation but that its activity is
modulated by C/EBP. The relative concentrations of each
transcription factor and the relative affinities to each other
and to DNA will ultimately determine whether the IL-8
promoter is activated or inhibited. Since adjacent C/EBP and
NF-KB binding sites are found in a variety of promoters, the
demonstrated functional and physical interaction between
these two transcription factor families might be a general
mechanism of cytokine-induced gene regulation.
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ADDENDUM IN PROOF
Two recent articles (W. Kaszubska, R. Hooft van Huijs-
duijnen, P. Ghersa, A.-M. DeRaemy-Schenk, B. P. C. Chen,
T. Hai, J. F. DeLamarter, and J. Whelan, Mol. Cell. Biol.
13:7180-7190, 1993; and W. Du, D. Thanos, and T. Maniatis,
Cell 74:887-898, 1993) demonstrate functional and physical
associations between the ATF bZIP proteins and NF-KB.
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